FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956124906> ?p ?o ?g. }

• W2956124906 endingPage "2751" @default.
• W2956124906 startingPage "2742" @default.
• W2956124906 abstract "Abstract Background Dual therapy combining integrase inhibitors and NNRTIs represents a promising regimen in ageing HIV-infected individuals with long exposure to nucleoside analogues and PIs. Methods The ANRS 163 ETRAL trial (NCT02212379) was a 96 week, multicentre, single-arm study evaluating the efficacy and safety of raltegravir (400 mg twice daily)/etravirine (200 mg twice daily) in individuals >45 years, on a PI-containing regimen who were integrase inhibitor and etravirine naive. The primary endpoint was the proportion of participants with virological success, defined by the absence of virological failure up to week 48. Main secondary outcomes included evolution of metabolic parameters, CD4/CD8 count, bone mineral density and inflammatory markers. The study was designed to show an efficacy >90%, assuming a success rate ≥95%, with a power of 80% and a 5% type-1 error. Results One hundred and sixty-five participants (median age 52 years, duration of ART 16.9 years, viral suppression 6.9 years and CD4 count 700 cells/mm3) were enrolled. By ITT analysis, viral suppression was maintained in 99.4% of participants (95% CI = 95.6%–99.9%) at week 48 and 98.7% (95% CI = 95.0%–99.7%) at week 96. Two virological failures occurred (week 24 and week 64) without emergence of integrase inhibitor resistance. Eight participants discontinued raltegravir/etravirine for adverse events, leading to a strategy success rate of 95.1% (95% CI = 90.5%–97.5%) at week 48 and 92.7% (95% CI = 87.5%–95.8%) at week 96. Over 96 weeks, lipid fractions improved (P < 0.001), CD4/CD8 ratio increased, IFNγ-induced protein 10 (IP-10) decreased (−8.1%), soluble CD14 decreased (−27%, P < 0.001) bone mineral density improved and BMI increased. Conclusions Raltegravir plus etravirine dual therapy demonstrated durable efficacy in virologically suppressed ageing patients." @default.
• W2956124906 created "2019-07-12" @default.
• W2956124906 creator A5003678988 @default.
• W2956124906 creator A5011828459 @default.
• W2956124906 creator A5012384299 @default.
• W2956124906 creator A5012384912 @default.
• W2956124906 creator A5014748606 @default.
• W2956124906 creator A5016215468 @default.
• W2956124906 creator A5017386021 @default.
• W2956124906 creator A5017799283 @default.
• W2956124906 creator A5020778242 @default.
• W2956124906 creator A5025251016 @default.
• W2956124906 creator A5029233916 @default.
• W2956124906 creator A5030300390 @default.
• W2956124906 creator A5035291390 @default.
• W2956124906 creator A5037609135 @default.
• W2956124906 creator A5039272561 @default.
• W2956124906 creator A5041968538 @default.
• W2956124906 creator A5044028812 @default.
• W2956124906 creator A5046238828 @default.
• W2956124906 creator A5050061959 @default.
• W2956124906 creator A5051532569 @default.
• W2956124906 creator A5053097790 @default.
• W2956124906 creator A5054112348 @default.
• W2956124906 creator A5056512475 @default.
• W2956124906 creator A5061527531 @default.
• W2956124906 creator A5063847487 @default.
• W2956124906 creator A5064601780 @default.
• W2956124906 creator A5068330062 @default.
• W2956124906 creator A5071438640 @default.
• W2956124906 creator A5081353121 @default.
• W2956124906 creator A5081538828 @default.
• W2956124906 creator A5086527016 @default.
• W2956124906 creator A5091495073 @default.
• W2956124906 date "2019-07-03" @default.
• W2956124906 modified "2023-10-16" @default.
• W2956124906 title "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study" @default.
• W2956124906 cites W2017480044 @default.
• W2956124906 cites W2036917641 @default.
• W2956124906 cites W2046246036 @default.
• W2956124906 cites W2053125329 @default.
• W2956124906 cites W2098152094 @default.
• W2956124906 cites W2099658521 @default.
• W2956124906 cites W2103115327 @default.
• W2956124906 cites W2103798805 @default.
• W2956124906 cites W2104218675 @default.
• W2956124906 cites W2106786687 @default.
• W2956124906 cites W2109423206 @default.
• W2956124906 cites W2116737560 @default.
• W2956124906 cites W2119711042 @default.
• W2956124906 cites W2135397849 @default.
• W2956124906 cites W2142982724 @default.
• W2956124906 cites W2150709496 @default.
• W2956124906 cites W2159328065 @default.
• W2956124906 cites W2166746687 @default.
• W2956124906 cites W2196190612 @default.
• W2956124906 cites W2311215932 @default.
• W2956124906 cites W2512407700 @default.
• W2956124906 cites W2562813092 @default.
• W2956124906 cites W2588956638 @default.
• W2956124906 cites W2593920469 @default.
• W2956124906 cites W2600324759 @default.
• W2956124906 cites W2621358721 @default.
• W2956124906 cites W2752494178 @default.
• W2956124906 cites W2761345412 @default.
• W2956124906 cites W2768049835 @default.
• W2956124906 cites W2781681713 @default.
• W2956124906 cites W2799633894 @default.
• W2956124906 cites W2802578844 @default.
• W2956124906 cites W2804884576 @default.
• W2956124906 cites W2806674111 @default.
• W2956124906 cites W2899935160 @default.
• W2956124906 cites W4252159325 @default.
• W2956124906 doi "https://doi.org/10.1093/jac/dkz224" @default.
• W2956124906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32954404" @default.
• W2956124906 hasPublicationYear "2019" @default.
• W2956124906 type Work @default.
• W2956124906 sameAs 2956124906 @default.
• W2956124906 citedByCount "25" @default.
• W2956124906 countsByYear W29561249062019 @default.
• W2956124906 countsByYear W29561249062020 @default.
• W2956124906 countsByYear W29561249062021 @default.
• W2956124906 countsByYear W29561249062022 @default.
• W2956124906 countsByYear W29561249062023 @default.
• W2956124906 crossrefType "journal-article" @default.
• W2956124906 hasAuthorship W2956124906A5003678988 @default.
• W2956124906 hasAuthorship W2956124906A5011828459 @default.
• W2956124906 hasAuthorship W2956124906A5012384299 @default.
• W2956124906 hasAuthorship W2956124906A5012384912 @default.
• W2956124906 hasAuthorship W2956124906A5014748606 @default.
• W2956124906 hasAuthorship W2956124906A5016215468 @default.
• W2956124906 hasAuthorship W2956124906A5017386021 @default.
• W2956124906 hasAuthorship W2956124906A5017799283 @default.
• W2956124906 hasAuthorship W2956124906A5020778242 @default.
• W2956124906 hasAuthorship W2956124906A5025251016 @default.
• W2956124906 hasAuthorship W2956124906A5029233916 @default.
• W2956124906 hasAuthorship W2956124906A5030300390 @default.
• W2956124906 hasAuthorship W2956124906A5035291390 @default.

• next